Skip to main content
. Author manuscript; available in PMC: 2021 Sep 22.
Published in final edited form as: Nat Metab. 2021 Mar 22;3(3):366–377. doi: 10.1038/s42255-021-00361-3

Table 1.

All qualified variants in PHGDH in 793 MacTel cases and 17610 controls under a dominant model with gnomAD MAF < 0.001.

Variant ID

Chr-Pos-Ref-Alt
HGVS.c HGVS.p Alleles in 793 MacTel cases Alleles in 17610 controls Allele frequency in gnomAD (if available) REVEL Polyphen2 HVAR CADD Relative enzyme activity to wt protein
1-120254666-GA-G c.21_22G p.Val9Cysfs*32 1
1-120254667-A-T c.22A>T p.Lys8Ter 1 39.0
1-120263820-G-A c.166G>A p.Ala56Thr 1 0.000004 0.53 B 24.9
1-120263835-G-A c.181G>A p.Ala61Thr 1 0.000046 0.53 P 27.5
1-120263880-G-T c.226G>T p.Ala76Ser 2 0.000099 0.78 D 32.0
1-120263896-A-T c.242A>T p.Asp81Val 1 0.000064 0.95 D 31.0
1-120263899-A-G c.245A>G p.Asn82Ser 2 0.000004 0.78 D 27.0
1-120263904-G-T c.250G>T p.Asp84Tyr 1 0.97 D 32.0
1-120263941-T-C c.287T>C p.Met96Thr 1 0.85 D 25.6 0.17
1-120266027-G-A c.319G>A p.Ala107Thr 1 2 0.000078 0.89 D 34.0
1-120266052-T-G c.344T>G p.Met115Arg 1 0.78 B 25.4 −0.01
1-120266064-G-C c.356G>C p.Arg119Thr 1 0.95 D 31.0
1-120269476-A-C c.359A>C p.Gln120Pro 1 0.64 B 23.5
1-120269497-C-T c.380C>T p.Ser127Leu 1 0.000016 0.74 D 35.0
1-120269654-A-C c.439A>C p.Thr147Pro 1 0.84 D 27.1
1-120269667-T-C c.452T>C p.Leu151Pro 1 0.93 D 28.0
1-120269682-T-C c.467T>C p.Ile156Thr 1 0.000018 0.92 D 29.2
1-120269720-A-G c.505A>G p.Met169Val 1 0.91 D 24.6
1-120277270-A-G c.524A>G p.Asp175Gly 1 0.97 D 33.0
1-120277272-C-G c.526C>G p.Pro176Ala 1 1 0.000008 0.85 D 29.3 1.34
1-120277282-C-G c.536C>G p.Ser179Cys 1 0.60 B 28.3
1-120277308-G-T c.562G>T p.Val188Phe 1 0.000004 0.80 D 32.0
1-120277318-T-A c.572T>A p.Leu191Gln 1 0.000039 0.66 P 23.3
1-120277365-A-T c.619A>T p.Thr207Ser 5 0.000052 0.78 P 26.6
1-120277384-C-T * c.638C>T p.Thr213Met 1 0.000008 0.96 D 34.0 0.13
1-120277956-G-C c.682G>C p.Gly228Arg 1 0.000004 0.86 D 31.0
1-120277956-G-T c.682G>T p.Gly228Trp 8 31 0.000843 0.88 D 33.0 0.17
1-120277980-C-T c.706C>T p.Arg236Cys 1 3 0.000060 0.79 D 34.0 0.19
1-120277981-G-A c.707G>A p.Arg236His 1 1 0.000036 0.81 D 32.0 0.14
1-120278004-G-A c.730G>A p.Ala244Thr 1 0.000028 0.80 D 26.7 0.23
1-120278016-G-A c.742G>A p.Ala248Thr 2 0.000016 0.88 D 34.0
1-120278040-G-A c.766G>A p.Gly256Arg 1 0.000012 0.94 D 34.0
1-120278046-G-T c.772G>T p.Ala258Ser 1 0.000008 0.71 P 28.2
1-120278065-A-G c.791A>G p.Glu264Gly 1 0.54 B 32.0
1-120279791-C-A c.847C>A p.His283Asn 1 0.94 D 34.0
1-120279801-C-T * c.857C>T p.Ala286Val 1 0.000004 0.92 D 34.0 0.11
1-120279825-G-A c.881G>A p.Arg294His 1 0.000095 0.71 P 31.0
1-120279833-G-T c.889G>T p.Glu297Ter 1 0.000004 43.0 −0.08
1-120279844-TG-T c.900_901T p.Val301Phefs*6 1
1-120283009-G-A c.946G>A p.Val316Met 1 0.000052 0.80 P 26.5
1-120283054-C-A c.991C>A p.Pro331Thr 1 0.000004 0.67 B 24.5
1-120283057-T-G c.994T>G p.Trp332Gly 1 0.67 P 29.7
1-120283093-C-T * c.1030C>T p.Arg344Ter 1 0.000017 37.0 0.47
1-120283117-G-T c.1054G>T p.Gly352Trp 1 0.53 P 32.0 0.76
1-120284447-T-C c.1136T>C p.Leu379Pro 1 0.95 D 28.1 0.23
1-120284516-T-G c.1205T>G p.Leu402Arg 1 0.80 D 26.6 0.47
1-120285493-G-A * c.1273G>A p.Val425Met 1 0.000004 0.74 P 28.7 0.45
1-120285545-C-T c.1325C>T p.Thr442Met 2 0.000004 0.55 B 12.3
1-120285569-G-T c.1349G>T p.Gly450Val 1 0.71 B 25.1
1-120285625-C-T c.1405C>T p.Arg469Trp 1 1 0.000016 0.61 D 24.0 0.36
1-120285626-G-A c.1406G>A p.Arg469Gln 1 3 0.000032 0.40 P 17.6 0.63
1-120285672-G-A c.1447+5G>A 1 14.0
1-120286529-G-A c.1468G>A p.Val490Met 1 5 0.000142 0.66 B 27.1 0.55
1-120286532-C-T c.1471C>T p.Arg491Trp 1 7 0.000103 0.53 B 29.7 0.52
1-120286568-G-C c.1507G>C p.Gly503Arg 2 0.000012 0.58 D 23.4
1-120286595-T-G c.1534T>G p.Ser512Ala 1 0.000024 0.64 B 21.3
1-120286599-C-G c.1538C>G p.Ser513Cys 1 0.50 P 24.0
1-120286599-C-T c.1538C>T p.Ser513Phe 1 0.58 P 25.2 0.85

All qualified variants (QVs) with gnomAD MAF < 0.001 in case and control cohorts are listed. These satisfy at least one of the following additional criteria: REVEL>0.5, Polyphen2 = P or D, Loss-of-function (stop-gain, frameshift, splicing). CADD values are shown for reference purpose only and were not used for variant qualification. A total of 29/793 (3.7%) cases and 99/17,610 (0.56%) of controls carried a single QV, resulting in two-sided FET p=1.2x10−13, OR = 6.7, 95% CI [4.2;10.3]. No cases or controls carried more than one QV. Pathogenicity of all variants present in MacTel cases was assessed by PHGDH enzymatic activity assay; results are shown in the last column. No data indicates no assay was performed, resulting in a conservative overestimate of pathogenic variants in the control cohort.

*

indicates variants that are causal in Neu-Laxova syndrome.